Crossmark

Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus

Published Online: 2024-07-10

Published Print: 2024-08

Authors

Bassett, Ryan L.

Gallo, Giovanni

Le, Kim-Phuong N. https://orcid.org/0000-0003-2693-1770
Volino, Lucio R.
License Information

Text and Data Mining valid from 2024-07-10

Version of Record valid from 2024-07-10
More Information

Article History

Received: 28 April 2024

Accepted: 29 June 2024

First Online: 10 July 2024

Compliance with ethical standards

:

: The authors declare no competing interests.

Document is current